✦ LIBER ✦

Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs)

✍ Scribed by M. Upadhyaya; Lan Kluwe; G. Spurlock; Bisma Monem; E. Majounie; K. Mantripragada; Martino Ruggieri; N. Chuzhanova; D.G. Evans; R. Ferner; N. Thomas; A. Guha; V. Mautner

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 364 KB
Volume: 29
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.20601

No coin nor oath required. For personal study only.

✦ Synopsis

Communicated by Riccardo Fodde

About 10% of neurofibromatosis type 1 (NF1) patients develop malignant peripheral nerve sheath tumors (MPNSTs) and represent considerable patient morbidity and mortality. Elucidation of the genetic mechanisms by which inherited and acquired NF1 disease gene variants lead to MPNST development is important. A study was undertaken to identify the constitutional and somatic NF1 mutations in 34 MPNSTs from 27 NF1 patients. The NF1 germline mutations identified in 22 lymphocytes DNA from these patients included seven novel mutations and a large 1.4-Mb deletion. The NF1 germline mutation spectrum was similar to that previously identified in adult NF1 patients without MPNST. Somatic NF1 mutations were identified in tumor DNA from 31 out of 34 MPNSTs, of which 28 were large genomic deletions. The high prevalence (490%) of such deletions in MPNST contrast with the Z 20% found in benign neurofibromas and is indicative of the involvement of different mutational mechanisms in these tumors. Coinactivation of the TP53 gene by deletion, or by point mutation along with NF1 gene inactivation, is known to exacerbate disease symptoms in NF1, therefore TP53 gene inactivation was screened. DNA from 20 tumors showed evidence for loss of heterozygosity (LOH) across the TP53 region in 11 samples, with novel TP53 point mutations in four tumors. Hum Mutat 29(1), 74-82, 2008.

📜 SIMILAR VOLUMES

Constitutional NF1 mutations in neurofib

Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors

✍ Lan Kluwe; Reinhard E. Friedrich; Matthias Peiper; Jan Friedman; Victor-F. Mautn 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB

Neurofibromatosis type 1 (NF1) patients have 10% of lifetime risk for developing malignant peripheral nerve sheath tumors (MPNST), one of the most aggressive cancers. We examined the spectrum of constitutional NF1 mutations among 24 NF1 patients with MPNST. We found mutations in 18 patients: four me

The heterogeneous nature of germline mut

The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs)

✍ Meena Upadhyaya; Gill Spurlock; Elisa Majounie; Sian Griffiths; Natalie Forreste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Malignant peripheral nerve sheath tumours (MPNSTs) are a major cause of mortality in patients with neurofibromatosis 1 (NF1). We have analysed lymphocyte DNA samples from 30 NF1 patients with MPNSTs to determine their underlying constitutional NF1 gene mutations. Mutations were detected in 27/30 (90

Germline and somatic NF1 gene mutations

Germline and somatic NF1 gene mutations in plexiform neurofibromas

✍ Meena Upadhyaya; Gill Spurlock; Bisma Monem; Nick Thomas; Reinhard E. Friedrich; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

Neurofibromatosis type 1 (NF1), a common autosomal dominant neurogenetic disorder affecting 1 in 4000 individuals worldwide, results from functional inactivation of the 17q11.2-located NF1 gene. Plexiform neurofibroma (PNF) is a congenital benign tumour present in 30-50% of NF1 patients, which in ab

Microarray-based copy number analysis of

Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho–GTPase pathway genes in NF1 tumorigenesis

✍ Meena Upadhyaya; Gill Spurlock; Laura Thomas; Nick S. T. Thomas; Mark Richards; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 479 KB

Neurofibromatosis type-1 (NF1) is associated with the growth of benign and malignant tumors. Approximately 15% of NF1 patients develop malignant peripheral nerve sheath tumors (MPNSTs), underlining the need to identify specific diagnostic/prognostic biomarkers associated with MPNST development. The

Characterization of the somatic mutation

Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors

✍ Meena Upadhyaya; Song Han; Claudia Consoli; Elisa Majounie; Martin Horan; Nick S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

## Communicated by Haig H. Kazazian One of the main features of neurofibromatosis type 1 (NF1) is benign neurofibromas, 10-20% of which become transformed into malignant peripheral nerve sheath tumors (MPNSTs). The molecular basis of NF1 tumorigenesis is, however, still unclear. Ninety-one tumors

Analysis of chromosomal imbalances in sp

Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization

✍ Gunhild Mechtersheimer; Marta Otaño-Joos; Sibylle Ohl; Axel Benner; Thomas Lehne 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

Peripheral nerve sheath tumors arise either sporadically or in association with neurofibromatosis type 1 (von Recklinghausen's neurofibromatosis, NF1) or type 2. In this study, comprehensive screening for relative chromosome copy number changes was performed on 10 benign and 19 malignant peripheral